News | October 19, 2009

RenalGuard Demonstrated in Live Case at GISE 2009

October 19, 2009 – PLC Systems Inc. today said its RenalGuard System will be utilized as part of a live case transmission from the Clinica Mediterranea, Naples, Italy, to the 30th Congresso Nazionale della Societa' Italiana di Cardiologia Invasiva (GISE), Oct. 20-23, in Bologna, Italy.

Dr. Carlo Briguori, chief of the laboratory of interventional cardiology, Clinica Mediterranea, a noted expert on CIN, is currently conducting an investigator-sponsored multicenter randomized clinical trial on the efficacy of RenalGuard at his hospital. He plans to make a presentation on the status of his study at GISE, and will include a video demonstrating the use of RenalGuard during his talk.

This live case transmission marks the second time RenalGuard has been utilized as part of a live case transmission during a cardiac procedure during a cardiology conference. In May 2009, RenalGuard was included as part of a live case transmission from Hospital Clinico San Carlos, Madrid, Spain, during the meeting of EuroPCR. The interventional cardiologists involved in that case demonstrated how RenalGuard is used to help prevent contrast-induced nephropathy (CIN) in a patient with impaired renal function undergoing a percutaneous coronary intervention (PCI).

Preliminary data from the first investigator-sponsored randomized clinical trial of RenalGuard, known as MYTHOS, has been presented at two international cardiology conferences, and indicates that patients at high risk for renal failure, when treated with RenalGuard while undergoing certain imaging procedures, acquired CIN at a significantly lower rate than those who were treated with overnight hydration. Acquiring CIN has been found to lead to a range of serious and potentially deadly outcomes in patients who already have compromised kidney function.

The investigators for this trial are Dr. Antonio L. Bartorelli, director, interventional cardiology, CCM, and professor of cardiology, University of Milan, and Dr. Giancarlo Marenzi, chief, intensive cardiac care unit at CCM, two of the world's leading experts on CIN.

For more information:

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging| August 18, 2017
August 18, 2017 — The American Society of...
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Cardiac Imaging| August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Magnetic Resonance Imaging (MRI)| August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
CDN to Integrate Advanced Cardiac Imaging Tools From DiA Imaging Analysis
Technology | August 10, 2017
August 10, 2017 — CDN recently announced a new partnership agreement with DiA Imaging Analysis Ltd., makers of next-g
Overlay Init